Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ELVN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Relcobatinib (ELVN-001) | Chronic Myeloid Leukemia (CML) | Phase 3 · NCT07905183 | Not yet recruiting |
| Fluorouracil | HER2-positive Breast Cancer | Phase 1 · NCT06328738 | Active not recruiting |
| HER2 Inhibitor ELVN-002 | HER2 Mutant Non-small Cell Lung Cancer | Phase 1 · NCT05650879 | Active not recruiting |
| Eribulin | HER2-positive Breast Cancer | Phase 1 · NCT06328738 | Active not recruiting |
| Trastuzumab Emtansine | HER2 Mutant Non-small Cell Lung Cancer | Phase 1 · NCT05650879 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not ELVN's own candidates): Dasatinib, Capecitabine, Fam-Trastuzumab Deruxtecan-Nxki, Leucovorin, Oxaliplatin, Paclitaxel, Trastuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ELVN holds $884.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.5M/quarter from operations, an estimated runway of 170.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 17 · Low
Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations into 2030.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELVN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 10,713,540 | 14.56% | 2026-06-30 |
| ORBIMED ADVISORS LLC 10% owner |
Insider | 6,555,102 | 8.91% | 2026-06-22 |
| BlackRock, Inc. | Institution (13G, 5%+) | 5,206,581 | 7.07% | 2026-09-30 |
| Polar Capital Holdings Plc | Institution (13G, 5%+) | 5,056,807 | 6.87% | 2026-03-31 |
| Commodore Capital LP | Institution (13G, 5%+) | 4,800,940 | 6.52% | 2026-03-31 |
| Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER · +112,500 options |
Insider | 758,938 | 1.03% | 2026-02-12 |
| Anish Patel CHIEF OPERATING OFFICER · +120,000 options |
Insider | 235,011 | 0.32% | 2026-02-12 |
| Richard A. Heyman Director · +19,234 options |
Insider | 149,218 | 0.20% | 2026-02-17 |
| Lori Anne Kunkel Director · +47,708 options |
Insider | 52,925 | 0.07% | 2026-10-30 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER · +409,966 options |
Insider | 38,000 | 0.05% | 2026-10-19 |
| Helen Louise Collins CHIEF MEDICAL OFFICER · +251,268 options |
Insider | 25,000 | 0.03% | 2026-10-19 |
Share count 73,595,132 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELVN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →